{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:52:50Z","timestamp":1790387570911,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Biogen Idec Austria"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.jneuroim.2011.03.001","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T06:06:21Z","timestamp":1301465181000},"page":"148-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells"],"prefix":"10.1016","volume":"234","author":[{"given":"Andrea","family":"Harrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wipfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Einhaeupl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Oppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Afazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Haschke-Becher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2011.03.001_bb0005","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1073\/pnas.0808909106","article-title":"Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity","volume":"106","author":"Bauer","year":"2009","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0010","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.4049\/jimmunol.0804356","article-title":"Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis","volume":"184","author":"Brahmachari","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0020","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab","volume":"65","author":"del Pilar","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jneuroim.2008.10.006","article-title":"Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis","volume":"206","author":"Dugger","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM198802043180507","article-title":"Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy","volume":"318","author":"Houff","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.drudis.2006.06.008","article-title":"The impact of interferon-beta treatment on the blood-brain barrier","volume":"11","author":"Kraus","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0404.1998.tb01727.x","article-title":"Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis","volume":"98","author":"Kraus","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0045","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis","volume":"71","author":"Krumbholz","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann","year":"2007","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","article-title":"Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients","volume":"194","author":"Lindberg","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2008.05.021","article-title":"Antigen-specific therapies in MS \u2014 current concepts and novel approaches","volume":"274","author":"Lutterotti","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0065","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2009.03.008","article-title":"alpha4 Integrin\/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions","volume":"210","author":"Man","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jneuroim.2011.03.001_bb0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jneuroim.2010.07.012","article-title":"Natalizumab treatment reduces endothelial activity in MS patients","volume":"227","author":"Millonig","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0080","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.drudis.2008.08.003","article-title":"Modern multiple sclerosis treatment \u2014 what is approved, what is on the horizon","volume":"13","author":"Pilz","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0090","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0100","first-page":"A293","article-title":"Double-blind, placebo-controlled randomized Phase II Serial MRI, safety and tolerability study of two doses of CDP323 in subjects with relapsing forms of multiple sclerosis over 24 weeks","volume":"74","author":"Polman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0105","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/archneur.62.10.1620","article-title":"Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis","volume":"62","author":"Stuve","year":"2005","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2011.03.001_bb0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00441-010-1023-3","article-title":"Invariant natural killer T cells: bridging innate and adaptive immunity","volume":"343","author":"Van Kaer","year":"2011","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","article-title":"Alpha4 integrins as therapeutic targets in autoimmune disease","volume":"348","author":"von Andrian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0120","doi-asserted-by":"crossref","unstructured":"Wipfler, P., Oppermann, K., Pilz, G., Afazel, S., Haschke-Becher, E., Harrer, A., Huemer, M., Kunz, A., Golaszewski, S., Staffen, W., Ladurner, G., Kraus, J. 2011. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult. Scler. 17 (1), 16\u201323.","DOI":"10.1177\/1352458510383075"},{"key":"10.1016\/j.jneuroim.2011.03.001_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572811000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572811000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:17:49Z","timestamp":1759047469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572811000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":25,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0165572811000634"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2011.03.001","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2011.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}